Symposium: Diabetes and CV risk - do the novel anti-diabetes medications offer new options and what are the main issues for GPs?
EPCCS Symposium to held at WONCA 2019Agenda - June 28, 2019 - Bratislava, Slovakia
If you are attending WONCA Europe 2019 conference we cordially invite you to attend the EPCCS symposium
European Primary Care Cardiovascular Society (EPCSS) Symposium 2: Diabetes and cardiovascular risk - do the novel anti-diabetes medications offer new options and what are the main issues for GPs?
What is the evidence for diabetes and risk of vascular disease? Can we quantify that risk? Is there evidence for interventions that can modify this risk and, if so, how are these interventions are initiated, dosed, and monitored, alongside any adverse effects and contra-indications? There are many recent and new data to guide this symposium.
Chair: Dr Michaela Macháčová, Bratislava and Professor Richard Hobbs, Oxford
- What’s the evidence that diabetes is linked to CVD? - Professor Richard Hobbs, University of Oxford, UK
- Update on managing CV risk in diabetes – what’s the evidence? - Professor Kamlesh Khunti, University of Leicester, UK
- Audience debate
Timing and location to be announced